Hyperphosphatemia News and Research

RSS
VITALE study: High-dose vitamin D effective in lowering fracture rates after kidney transplantation

VITALE study: High-dose vitamin D effective in lowering fracture rates after kidney transplantation

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Eagle Biosciences launches novel Intact FGF23 ELISA Assay Kit

Eagle Biosciences launches novel Intact FGF23 ELISA Assay Kit

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Ardelyx initiates two clinical trials to evaluate new treatment for hyperkalemia

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx signs termination agreement with AstraZeneca, regains rights to portfolio of NHE3 inhibitors

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

OPKO Health acquires Cytochroma

OPKO Health acquires Cytochroma

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia